Search

A 47-year-old non-smoker male who has received the first dose of the BNT162b2 mRNA Covid-19 vaccine in Saudi Arabia. At day 3 post-vaccination, he tested negative for Covid-19 and travelled to Egypt. On day 12 he developed runny nose, body ache and fever, and he reportedly tested (PCR) negative for Covid-19 Upon his return to Saudi on day 15, his symptoms have worsened and he presented to the Emergency Department, at which he tested positive for Covid-19. The patient was overweight (BMI = 29), was not suffering from any comorbidities and was not taking any medication. Upon examination, he was vitally stable and his laboratory investigation only revealed a slightly increased Creatinine. His chest X-ray was unremarkable. His condition did not require hospital admission, so he was discharged and advised to home-isolate himself. Four days after his discharge, his entire household came to the hospital and tested positive for Covid-19. This is the first case report, in Saudi Arabia, of a person receiving the first dose of the BNT162b2 vaccine and got infected with Covid-19 afterwards. The report highlights the significance of receiving the second dose of the vaccine to be effective. It also demonstrates that those with a single dose mRNA vaccine, could get infected and transmit the infection. [ABSTRACT FROM AUTHOR]

Schiff base metal complexes are considered promising chemotherapeutic agents due to their potential application in cancer therapy. The current work sought to synthesize a brand-new Schiff base ligand obtained from 2-hydroxybenzohydrazide and (E)− 1-(2-(p-tolyl)hydrazono)propan-2-one with metal ions which included Pd(II) and Zn(II) ions. Elemental analyses, FT-IR, mass spectra, 1H NMR, UV-Vis spectrometer, and computational analysis characterized the compound's structure. In vitro, the breast cancer cell line (MCF-7) was tested for its sensitivity to Schiff base (HL) and its Pd(II) and Zn(II) complexes. The half-maximal inhibitory concentration IC 50 of the compounds was determined and used to perform the comet assay, which was carried out to reveal the photo-induced DNA damaging ability of the compounds of individual cells. Moreover, the compounds' effects on antioxidant defense systems of enzymes in cells: superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities and oxidant Malondialdehyde (MDA) were examined in MCF-7 cells. The Pd(II) complex displayed approximately the same IC 50 as Cisplatin, while Zn(II) complex had better activity than Cisplatin with very low IC 50 , 1.40 μg/ml. Significant alterations in SOD, CAT, GPx, and MDA production were discovered, inducing oxidative stress, enlarging ROS production, and reducing the antioxidant amount. This change was approximately similar in most compounds. Consequently, it promoted apoptosis, particularly the Zn(II) complex, which demonstrated an improved impact because of its ability to influence the antioxidant defense systems of enzymes, mostly SOD and GPx, besides increasing MDA levels. It can be concluded that Zn(II) complex is the most effective anticancer drug since it induced a very similar genotoxic effect as Cisplatin and has a very low IC 50 value. • New Schiff base ligand obtained from 2-hydroxybenzohydrazide and (E)− 1-(2-(p-tolyl)hydrazono)propan-2-one was synthesized. • The new Schiff base ligand contained metal ions which included Pd(II) and Zn(II) ions. • Zn(II) complex was the most effective anticancer drug. [ABSTRACT FROM AUTHOR]